Unlock the Editor’s Digest without spending a dime
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly e-newsletter.
A Novo Nordisk weight-loss drug is protected and efficient in youngsters as younger as six, based on a brand new company-funded examine, paving the way in which for liraglutide to grow to be the primary therapy for weight problems to be made obtainable to the age group.
Kids aged 6 to 12 utilizing the injectable pens for simply over a yr noticed a 7.4 per cent discount of their body-mass index in contrast with these on a placebo, based on the trial.
Liraglutide is a diabetes and weight-loss therapy in the identical GLP-1 class of medication as Novo Nordisk’s blockbuster Ozempic and Wegovy remedies.
The ends in the examine, which concerned 82 youngsters, come as Novo Nordisk of Denmark and US rival Eli Lilly search to increase the usage of GLP-1s by exhibiting their advantages in additionally tackling illnesses linked to weight problems, resembling coronary heart illness, and growing capsule variations of the merchandise to be taken orally.
Martin Holst Lange, the corporate’s head of improvement, mentioned the drugmaker will search regulatory approval from the US Meals and Drug Administration and from the European Medicines Company to increase the usage of liraglutide to under-12s.
“One in 5 youngsters have weight problems and one of many largest predictors for grownup weight problems is childhood weight problems so having this potential intervention for that age group is necessary,” Lange instructed the Monetary Instances.
Contributors within the trial had beforehand undergone life-style therapy that had proved ineffective.
There are presently no pharmaceutical remedies accredited for normal weight problems in under-12s — versus that discovered with some uncommon genetic problems — mentioned Claudia Fox, a professor from College of Minnesota Medical College who led the examine, which may also be revealed within the New England Journal of Drugs.
Novo Nordisk can also be testing semaglutide — the energetic ingredient in Ozempic and Wegovy — for younger youngsters. The therapy is already accredited for over-12s and delivers increased weight reduction than liraglutide.
However as with adults, the drug did result in unintended effects of nausea and vomiting, and those that stopped utilizing it regained weight rapidly, an indication of the constraints in treating weight problems by means of medication.
Nevertheless, Fox mentioned there have been no variations between the management group on placebos and people on liraglutide when it comes to progress, adjustments in bone age or points with puberty.
“That does present some consolation however . . . we want a lot longer-term information and far greater numbers. We’ll see whether or not the FDA say if that is satisfactory for regulatory approval or not,” Fox mentioned.
New evaluation by information supplier PitchBook suggests the weight problems drug market will peak at $200bn in worth, with Novo Nordisk and US firm Eli Lilly set to proceed to dominate the sector regardless of rivals resembling Roche and Amgen launching challenger merchandise.
The Danish drugmaker has invested heavily in analysis and improvement to provide you with successor remedies to Ozempic and Wegovy.
One potential candidate watched intently by analysts is amycretin, a drug that mixes the results of GLP-1, a hormone discovered within the intestine, with amylin, a hormone within the pancreas that additionally impacts urge for food regulation.
At a diabetes convention in Madrid, the Danish firm additionally unveiled early information for a every day oral capsule referred to as amycretin. Customers on a most dose misplaced 13 per cent of their physique weight over three months, with out the autumn levelling off.
Whereas stressing that the info was early, Lange mentioned the drug “has potential that’s on a par with CagriSema”, one other Novo Nordisk product in later-stage trials it believes may present 25 per cent weight reduction, in comparison with round 15 per cent for Wegovy and round 20 per cent supplied by Eli Lilly’s Mounjaro drug.
Nevertheless, he mentioned there was “little question” the capsule would require increased quantities of energetic pharmaceutical components in comparison with injectable pens, including to stress on the corporate’s provide chains. Wegovy and Ozempic have repeatedly suffered shortages resulting from excessive demand for the medication.
Naveed Sattar, professor of metabolic medication at Glasgow College, mentioned the info on amycretin was “thrilling given the pace of weight reduction seen” however that “far larger-scale trials” can be wanted to check the medication’s potential.
